Citizens Rates Exelixis (EXEL) buy, $55 Price Target

Citizens keeps its buy rating for Exelixis, setting a $55 target, a 3.33% upside from the current price.

By EarningsIQ Research Desk · Published Jun 24, 2026, 10:02 AM EDT · Updated Jun 26, 2026, 12:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Citizens rated Exelixis, Inc. ($EXEL) "buy" with a $55 price target on June 24, 2026.

Since the rating, $EXEL is up 2.1% after 1 week, up 4.7% after 1 month and up 17.7% to date (from the $52.87 close on Jun 24, 2026).

EXEL Exelixis, Inc.

$62.23 +42.79% year to date

Daily close · Oct 16, 2026

Key Points

Citizens reiterated its buy rating on Exelixis, Inc. (EXEL) with a price target of $55 on June 24, 2026.
Citizens's $55 price target implies 3.33% upside from Exelixis, Inc.'s ($EXEL) current $53.23 share price.
Exelixis shares traded at $51.34 on Wednesday, with a market cap of $12.9 billion and a P/E ratio of 17.0.
Recent insider transactions include planned sales by executives and a series of buys by directors in late May 2026.

Get $EXEL trade alerts by text

We text you when insiders, Congress or big funds trade $EXEL. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Exelixis, Inc. alert may contain errors. Disclosures

Citizens has maintained its buy rating for Exelixis, Inc. (NasdaqGS: EXEL) and set a price target of $55. This reiteration by analyst Silvan Turkcan was announced on June 24, 2026. Shares of Exelixis traded at $51.34 on Wednesday.

Exelixis, Inc. Stock Down 8.8%

Exelixis, Inc. has a market capitalization of approximately $12.9 billion. The company's stock currently trades with a P/E ratio of 17.0 and a forward P/E of 12.7. Its beta, a measure of volatility, stands at 0.435. Over the past 52 weeks, the stock has ranged from a low of $33.76 to a high of $53.93. The 50-day moving average is $48.53, while the 200-day moving average is $43.49. Exelixis also maintains a solid current ratio of 3.26 and a quick ratio of 3.01, with a debt-to-equity ratio of 8.76.

12-month forecast

$EXEL price target

Exelixis, Inc. daily closes and this analyst's $55 target. Not advice.

Recent Earnings

For its most recent financial period, Exelixis reported revenue of $2.38 billion, reflecting a growth rate of 10%. The company achieved a net margin of 35.1% and a return on equity (ROE) of 41.0%. Earnings per share (EPS) were $3.02. The next earnings report is scheduled for August 4, 2026.

Insider Buying and Selling at Exelixis, Inc.

Recent insider activity at Exelixis includes several transactions. On June 1, 2026, Sue Gail Eckhardt sold 9,812 shares at an average price of $50.14, and Jack Wyszomierski sold 3,925 shares at $50.55, both as planned sales. In contrast, on May 27, 2026, multiple directors, including Bob Oliver, Stelios Papadopoulos, Jack Wyszomierski, and Tomas Heyman, each acquired 8,367 shares in non-planned purchases.

Analysts Set New Price Targets

On June 24, 2026, Citizens maintained its buy rating on Exelixis with a $55 price target. Other firms have also weighed in recently. On May 7, 2026, HC Wainwright & Co. maintained a buy rating with a $56 target. TD Cowen also kept a buy rating with a $55 target on May 6, 2026. Meanwhile, firms like Morgan Stanley, Stifel, and Wells Fargo have maintained hold ratings with targets ranging from $40 to $50. The consensus among 16 analysts is a buy recommendation, with an average target price of $49.

About Exelixis, Inc.

Exelixis, Inc. is a biotechnology company based in Alameda, California, focused on developing treatments for cancer. The company is known for its CABOMETYX and COMETRIQ products, which are used to treat various types of cancer. Led by CEO Dr. Michael M. Morrissey, the company employs 1,077 people and engages in research collaborations with several major pharmaceutical firms.

Bottom Line

Citizens' reiteration of a buy rating for Exelixis, Inc. with a $55 price target reflects confidence in the company's potential. Investors and analysts alike are watching Exelixis closely, given its robust financial performance and strategic partnerships in cancer treatment. While the latest analyst ratings provide insight, it's important to remember that these are backward-looking statements and may not reflect future performance.